HFB-200603

N/A

Report date: 2023/01/09 10:32:50

Base Information

Drug NameHFB-200603
Drug Alias NameHFB-200603
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionB- and T-lymphocyte attenuator blockers
TargetsB- and T-lymphocyte attenuator
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalySpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHiFiBiO Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesHiFiBiO Therapeutics
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A